Mylan Launches First Generic ORTHO EVRA® Patch
PR Newswire - Wed Apr 16, 3:13PM CDT
Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched XULANE(TM) (Norelgestromin / Ethinyl Estradiol Transdermal System 150/35 mcg per day), the generic version of Janssen Pharmaceuticals Inc.'s ORTHO EVRA®* (Norelgestromin / Ethinyl Estradiol Transdermal System 150/35 mcg per day). This product is indicated for the prevention of pregnancy in women who elect to use a transdermal patch as a method of contraception. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product.
Mylan Inks Two Separate Agreements - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 10:10AM CDT
Mylan entered into two separate agreements with Prosonix and Actavis.
Wednesday’s Top Health Care Stories: Zogenix, Endo, and Teva
Leo Sun, The Motley Fool - Motley Fool - Wed Apr 16, 8:21AM CDT
Let's take a quick look at three stocks -- Zogenix , Endo International , and Teva Pharmaceutical -- which could all loom large in health care headlines this morning. Zogenix surges after a U.S. court reverses the Massachusetts ban on...
Prosonix partners with Mylan for global development and commercialisation of generic inhaled respiratory products
M2 - Wed Apr 16, 3:39AM CDT
Specialist pharmaceutical company Prosonix disclosed on Tuesday the launch of a global licensing agreement for its leading inhaled respiratory products, PSX1001 and PSX1050, in partnership with Mylan (NasdaqGS:MYL), a pharmaceutical company.
Mylan (MYL) Crosses Pivot Point Support at $45.22
Comtex SmarTrend(R) - Tue Apr 15, 11:46AM CDT
Shares of Mylan (NASDAQ:MYL) have bearishly opened below the pivot of $46.12 today and have reached the first support level of $45.22. Analysts will be watching for a cross of the next downside pivot targets of $44.40 and $42.68.
Mylan Announces Settlement Agreement for First-to-File Generess® Fe
PR Newswire - Tue Apr 15, 9:20AM CDT
Mylan Inc. (Nasdaq: MYL) today confirmed that it and its partner Famy Care Ltd. have entered into a settlement and license agreement with Warner Chilcott Company, LLC, settling the parties' litigation in connection with Mylan's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Norethindrone and Ethinyl Estradiol Chewable Tablets 0.8 mg/0.025 mg and Ferrous Fumarate Chewable Tablets. This product is the generic version of Generess® Fe Tablets, which are indicated for the prevention of pregnancy (1).
Mylan Launches Generic Lunesta® Tablets
PR Newswire - Tue Apr 15, 9:08AM CDT
Mylan Inc. (Nasdaq: MYL) today announced that it has launched Eszopiclone Tablets 1 mg, 2 mg and 3 mg, the generic version of Sunovion Pharmaceuticals Inc.'s Lunesta®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of insomnia.
Tuesday’s Top Health Care Stories: Johnson & Johnson, Teva, Mylan, and Dynavax
Leo Sun, The Motley Fool - Motley Fool - Tue Apr 15, 8:24AM CDT
Let's take a quick look at four stocks -- Johnson & Johnson , Teva , Mylan , and Dynavax -- which could all loom large in health care news this Tuesday morning. Johnson & Johnson reports first quarter earnings, raises...
Prosonix and Mylan Enter Into Global Licensing Agreement for Generic Versions of Inhaled Respiratory Products Flixotide(R) and Flovent(R)
PR Newswire Europe - Tue Apr 15, 7:02AM CDT
OXFORD, England and PITTSBURGH, Pennsylvania, April 15, 2014 /PRNewswire/ --
Prosonix and Mylan Enter Into Global Licensing Agreement for Generic Versions of Inhaled Respiratory Products Flixotide® and Flovent®
PR Newswire - Tue Apr 15, 7:00AM CDT
Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, today announced that it has entered into a global licensing agreement with Mylan Inc. (Nasdaq: MYL), one of the world's leading global pharmaceutical companies, for its leading inhaled respiratory products, PSX1001 and PSX1050.
Legal Updates, Stock Price Movements, New Awareness Campaigns, and Senior-level Appointments - Analyst Notes on Mylan, WellPoint, Forest, Novatis and Intercept
PR Newswire - Tue Apr 15, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Mylan Inc. (NASDAQ: MYL), WellPoint Inc. (NYSE: WLP), Forest Laboratories Inc. (NYSE: FRX), Novatis AG (NYSE: NVS) and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1162-100free.
Mylan to Settle with Endo on Frova - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 10:40AM CDT
A federal district court granted Mylan's request to forge a settlement with Endo regarding Frova.
Mylan announces favourable settlement agreement with Endo Pharmaceuticals for Frovatriptan Succinate Tablets, 2.5 mg
M2 - Mon Apr 14, 9:05AM CDT
Pharmaceutical company Mylan (NasdaqGS:MYL) said on Friday that the federal district court has granted its request to enforce a settlement agreement with Endo Pharmaceuticals for Frovatriptan Succinate Tablets, 2.5 mg.
Is Teva Pharmaceutical Industries Ltd. Destined for Greatness?
Alex Planes, The Motley Fool - Motley Fool - Mon Apr 14, 8:30AM CDT
Investors love stocks that consistently beat the Street without getting ahead of their fundamentals and risking a meltdown. The best stocks offer sustainable market-beating gains, with robust and improving financial metrics that support strong price...
The Hepatitis C Cure Poised to "Break the Country"
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Sat Apr 12, 7:05AM CDT
Gilead 's Sovaldi is reportedly flying off the shelves, but bad press due to pushback from payers, members of Congress, and even the WHO continues to roll in. At issue is the high price of Sovaldi in the U.S. -- $84,000 for a full course of...
After Yesterday's Decline of 2.87%, Mylan Offers Investors Better Value
Comtex SmarTrend(R) - Fri Apr 11, 4:52PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $45.41 to a high of $47.03. Yesterday, the shares fell 2.9%, which took the trading range below the 3-day low of $45.80 on volume of 7.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Watch for Mylan to Potentially Rebound After Falling 2.87% Yesterday
Comtex SmarTrend(R) - Fri Apr 11, 4:52PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $45.41 to a high of $47.03. Yesterday, the shares fell 2.9%, which took the trading range below the 3-day low of $45.80 on volume of 7.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Acura Pharma Ends Agreement with Pfizer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 4:35PM CDT
Acura Pharmaceuticals entered into a letter agreement with Pfizer in connection with its license agreement for Oxecta.
Campaign for Wider Reach, Clinical Trial Results, Recognitions, Earnings Release Schedule, and Favorable Ruling - Analyst Notes on Cigna, Medtronic, WellPoint, Mylan, and Express Scripts
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Cigna Corp. (NYSE: CI), Medtronic, Inc. (NYSE: MDT), WellPoint Inc. (NYSE: WLP), Mylan, Inc. (NASDAQ: MYL), and Express Scripts Inc. (NASDAQ: ESRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register